Market capitalization | $145.40m |
Enterprise Value | $45.46m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.87 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-117.71m |
Free Cash Flow (TTM) Free Cash Flow | $-89.54m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
8 Analysts have issued a Adverum Biotechnologies Inc forecast:
8 Analysts have issued a Adverum Biotechnologies Inc forecast:
Dec '23 | |
Current assets | 103 103 |
Fixed assets | 70 70 |
Total Assets | 173 173 |
Dec '23 | |
Equity | 83 83 |
Debt capital | 90 90 |
Total Capital | 173 173 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Laurent Fischer |
Employees | 121 |
Founded | 2006 |
Website | www.adverum.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.